Genedrive Share Discussion Threads

[ghost_walker] 24/7/2024 20:57

Z1CO24 Jul '24 - 21:53 - 6475 of 6475
0 0 0
Cobra

Peeps have been selling these sub 2p and saying exactly the same what you're saying that it won't go any higher.

Most traders like you say the same after selling.

A minimum of 8p to 10p when approval is confirmed next week


Z1CO - 17 Jul 2024 - 08:24:50 - 959 of 1074 Shares are poised to rebound very strongly - GDR
So far i have sold 2.15m shares and have another 1.1m to go.

Happy to have got well over 4p on all my trades so far.

[z1co] 24/7/2024 20:53

Cobra

Peeps have been selling these sub 2p and saying exactly the same what you're saying that it won't go any higher.

Most traders like you say the same after selling.

A minimum of 8p to 10p when approval is confirmed next week

[ghost_walker] 24/7/2024 20:52

The bearded child from Kabul is working hard overtime, alas, that -80% is coming, and will finish this baby rapist

[cobra kai] 24/7/2024 20:49

Bones

I sold yesterday, it's priced in now. Up 166% from the placing price.

It will be sell on the news.

NICE giving a go does not mean anything to the bottom line in the short term.

[z1co] 24/7/2024 20:48

The markets that the Company is targeting are significant relative to its size. The Company estimates the global overall market opportunity of its AIHL and CYP2C19 assays is over £300 million per annum.

For MT-RNR1 ID kit the company estimates that the total addressable UK market is up to £8.5 million per annum which is based on approximately 100,000 NICU admissions per annum and an estimated customer price per test of more than £80. The EU market is potentially another c.£46.75 million per annum, the U.S. market is c.£34 million and rest of World markets around £13.75 million. Market estimates are based on end user pricing.

For CYP2C19-ID Kit the Company estimates that the total addressable UK market is up to £8.5 million per annum, based on the assumption that there are over 100,000 strokes per annum and an estimated customer price per test of approximately £100. The EU market is estimated to be c.£93.5 million, the U.S. market is c.£67.6 million and rest of the world markets approximately £51 million. Market estimates are based on end user pricing.

[z1co] 24/7/2024 20:47

Well done bones

[cobra kai] 24/7/2024 20:46

I took profit yesterday; I am waiting on the sideline line; it's priced in now, 166% from the placing price.

Most likely sell on the news. If it's bad news, well, back to placing price or below

[bones698] 24/7/2024 20:40

Genghis the difference is Gdr have just raised funds so won't be able to take it private without paying the going rate now as they can't use the excuse they can't raise money. The difference with dest is they didn't want to do a madsivelybdillutive raise eandnt0jinknits better to duelist to try and raise money. Wethwr they are right or not remains to be seenfornkenthisnusjally happens when the ceo thinks the company is worth more than it relaly is and can't accept getting wiped out m they decide to go private but it's a gamble and many are never seen again. Shareholders wiped out totally.

Here that isn't happening yet anyway, and soon provided they start to deliver with the NHS the share price will. Be much higher and provide better options in the future.

Nice to see the scarmongers trying desperately to talk it down. NICE news will come and with it the realisation they are out of the game when the share price continues to rise.

[z1co] 24/7/2024 20:39

Hey Batiboy

GDR already has MT-RNR1 ID Kit APPROVED from last year and are very close to getting their 2nd test APPROVED next week.

That's the BIG difference between GDR and DEST

The company is already beginning to generate revenue which will increase significantly over the coming years and eventually the company will be making huge profits.

[ghost_walker] 24/7/2024 20:34

Money raised with PH won't last long

possibly delisting.

Batiatus24 Jul '24 - 12:49 - 21 of 25
0 0 0
Destiny Pharma PLC

Refer to their 15 July 2024 RNS

"As previously disclosed, the Company has been seeking a licencing partner for the development of XF-73 Nasal through Phase 3 clinical trials. However, to date a deal has not been forthcoming and given our cash runway, the Board and our advisors have been evaluating a range of strategic options to access the significant quanta of funding required to progress the drug through these Phase 3 clinical trials and realise the creation of meaningful shareholder value.

"This review, and our discussions with possible funding partners, has identified that a larger pool of capital may be available to Destiny Pharma as a private company and therefore, the Board has concluded that delisting from AIM and re-registering as a private company is a necessary step to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials and bring this important product to patients and health systems."

Back to GDR and their funding and strategy, which is no where to be seen in their current position. There is also the risk of Cheek taking the company private?

Remember he refused to comment in the last presentation when a shareholder asked.

Another risk at play? Any thoughts?

Genuinely question from me, how does the company get away with shafting shareholders like that?

[ghost_walker] 24/7/2024 20:32

Z1CO16 Jul '24 - 22:07 - 947 of 1048
0 3 1
The last delay by NICE was announced by the company at 9.28am yet a lot already knew over night and started selling at the open.

Same could happen again

[ghost_walker] 24/7/2024 20:32

Batiatus24 Jul '24 - 12:49 - 21 of 25
0 0 0
Destiny Pharma PLC

Refer to their 15 July 2024 RNS

"As previously disclosed, the Company has been seeking a licencing partner for the development of XF-73 Nasal through Phase 3 clinical trials. However, to date a deal has not been forthcoming and given our cash runway, the Board and our advisors have been evaluating a range of strategic options to access the significant quanta of funding required to progress the drug through these Phase 3 clinical trials and realise the creation of meaningful shareholder value.

"This review, and our discussions with possible funding partners, has identified that a larger pool of capital may be available to Destiny Pharma as a private company and therefore, the Board has concluded that delisting from AIM and re-registering as a private company is a necessary step to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials and bring this important product to patients and health systems."

Back to GDR and their funding and strategy, which is no where to be seen in their current position. There is also the risk of Cheek taking the company private?

Remember he refused to comment in the last presentation when a shareholder asked.

Another risk at play? Any thoughts?

Genuinely question from me, how does the company get away with shafting shareholders like that?

[batiatus] 24/7/2024 20:24

Z1co is here 24/7. Its his job.
All he is doing is copy and pasting scripts.

[z1co] 24/7/2024 20:13

The markets that the Company is targeting are significant relative to its size. The Company estimates the global overall market opportunity of its AIHL and CYP2C19 assays is over £300 million per annum.

For MT-RNR1 ID kit the company estimates that the total addressable UK market is up to £8.5 million per annum which is based on approximately 100,000 NICU admissions per annum and an estimated customer price per test of more than £80. The EU market is potentially another c.£46.75 million per annum, the U.S. market is c.£34 million and rest of World markets around £13.75 million. Market estimates are based on end user pricing.

For CYP2C19-ID Kit the Company estimates that the total addressable UK market is up to £8.5 million per annum, based on the assumption that there are over 100,000 strokes per annum and an estimated customer price per test of approximately £100. The EU market is estimated to be c.£93.5 million, the U.S. market is c.£67.6 million and rest of the world markets approximately £51 million. Market estimates are based on end user pricing.

[z1co] 24/7/2024 20:10

The markets that the Company is targeting are significant relative to its size. The Company estimates the global overall market opportunity of its AIHL and CYP2C19 assays is over £300 million per annum.

For MT-RNR1 ID kit the company estimates that the total addressable UK market is up to £8.5 million per annum which is based on approximately 100,000 NICU admissions per annum and an estimated customer price per test of more than £80. The EU market is potentially another c.£46.75 million per annum, the U.S. market is c.£34 million and rest of World markets around £13.75 million. Market estimates are based on end user pricing.

For CYP2C19-ID Kit the Company estimates that the total addressable UK market is up to £8.5 million per annum, based on the assumption that there are over 100,000 strokes per annum and an estimated customer price per test of approximately £100. The EU market is estimated to be c.£93.5 million, the U.S. market is c.£67.6 million and rest of the world markets approximately £51 million. Market estimates are based on end user pricing.

[premium beeks] 24/7/2024 20:10

Looks to be working. Good stuff.

[premium beeks] 24/7/2024 19:41

Internet update Z1co?

[genghis_khan_] 24/7/2024 19:20

Money raised with PH won't last long

possibly delisting.

Batiatus24 Jul '24 - 12:49 - 21 of 25
0 0 0
Destiny Pharma PLC

Refer to their 15 July 2024 RNS

"As previously disclosed, the Company has been seeking a licencing partner for the development of XF-73 Nasal through Phase 3 clinical trials. However, to date a deal has not been forthcoming and given our cash runway, the Board and our advisors have been evaluating a range of strategic options to access the significant quanta of funding required to progress the drug through these Phase 3 clinical trials and realise the creation of meaningful shareholder value.

"This review, and our discussions with possible funding partners, has identified that a larger pool of capital may be available to Destiny Pharma as a private company and therefore, the Board has concluded that delisting from AIM and re-registering as a private company is a necessary step to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials and bring this important product to patients and health systems."

Back to GDR and their funding and strategy, which is no where to be seen in their current position. There is also the risk of Cheek taking the company private?

Remember he refused to comment in the last presentation when a shareholder asked.

Another risk at play? Any thoughts?

Genuinely question from me, how does the company get away with shafting shareholders like that?

[genghis_khan_] 24/7/2024 19:19

Batiatus24 Jul '24 - 12:49 - 21 of 25
0 0 0
Destiny Pharma PLC

Refer to their 15 July 2024 RNS

"As previously disclosed, the Company has been seeking a licencing partner for the development of XF-73 Nasal through Phase 3 clinical trials. However, to date a deal has not been forthcoming and given our cash runway, the Board and our advisors have been evaluating a range of strategic options to access the significant quanta of funding required to progress the drug through these Phase 3 clinical trials and realise the creation of meaningful shareholder value.

"This review, and our discussions with possible funding partners, has identified that a larger pool of capital may be available to Destiny Pharma as a private company and therefore, the Board has concluded that delisting from AIM and re-registering as a private company is a necessary step to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials and bring this important product to patients and health systems."

Back to GDR and their funding and strategy, which is no where to be seen in their current position. There is also the risk of Cheek taking the company private?

Remember he refused to comment in the last presentation when a shareholder asked.

Another risk at play? Any thoughts?

Genuinely question from me, how does the company get away with shafting shareholders like that?